Clinical COPD Questionnaire

Abstract

The Clinical COPD Questionnaire (CCQ) is a widely validated, self-administered patient-reported outcome measure (PROM) designed to evaluate health-related functional status, symptomatic burden, and emotional well-being in individuals diagnosed with chronic obstructive pulmonary disease (COPD). Developed by Thys van der Molen and colleagues in 2003, the CCQ bridges the divide between complex, research-oriented health status instruments—such as the St. George’s Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Questionnaire (CRQ)—and the practical constraints of routine clinical practice. Composed of 10 items divided across three distinct clinical domains (Symptoms, Functional State, and Mental State), the CCQ assesses respiratory morbidity using either a 24-hour or a 7-day recall window. Each item is scored on an authentic 7-point Likert scale ranging from 0 (no impairment/asymptomatic) to 6 (maximum impairment/severely symptomatic). The overall score represents the unweighted arithmetic mean of all 10 items, yielding a composite index between 0 and 6, where higher scores signify poorer clinical health status.

Psychometrically, the CCQ exhibits exceptional measurement properties across mild, moderate, severe, and very severe COPD phenotypes. Internal consistency reliability is high, with overall Cronbach’s alpha values typically ranging between 0.87 and 0.91, and subscale alphas consistently exceeding 0.75. Test-retest reliability coefficients demonstrate high temporal stability over periods of clinical stability (intraclass correlation coefficients generally between 0.90 and 0.95). Exploratory and confirmatory factor analyses robustly substantiate the instrument’s three-dimensional structure while supporting a unidimensional higher-order construct of COPD-specific health status. Furthermore, the CCQ demonstrates strong convergent validity with established legacy measures (correlating strongly with SGRQ total scores at r = 0.69 to 0.81), moderate cross-sectional correlations with physiological indices such as forced expiratory volume in one second (FEV₁ % predicted), and acute sensitivity to therapeutic interventions, including pulmonary rehabilitation and exacerbation recovery. The established minimal clinically important difference (MCID) is approximately 0.4 points, providing clinicians and researchers with an intuitive metric for identifying clinically meaningful changes.

Keywords

Clinical COPD Questionnaire, CCQ, Chronic Obstructive Pulmonary Disease, Patient-Reported Outcome Measures, Health-Related Quality of Life, Respiratory Symptoms, Functional Limitation, Psychometrics, Validation, Minimal Clinically Important Difference

Authors

The Clinical COPD Questionnaire was conceptualized, developed, and psychometrically validated by a multidisciplinary team of pulmonary physicians, general practitioners, and clinical epidemiologists from the Netherlands and Canada:

• Thys van der Molen, MD, PhD — Department of General Practice, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands. Professor of Primary Care Respiratory Medicine.
• B. W. M. Willemse, MD, PhD — Department of Pulmonology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
• S. Schokker, MSc — Department of General Practice, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
• Nick H. T. Ten Hacken, MD, PhD — Department of Pulmonology and Tuberculosis, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
• Dirkje S. Postma, MD, PhD — Department of Pulmonology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Renowned investigator in airway obstruction and asthma/COPD genetics.
• Elizabeth F. Juniper, MCSP, MSc — Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada. Leading expert in respiratory health status and quality-of-life methodology.

Correspondence regarding original development and academic permissions has historically been administered through the Department of General Practice at the University Medical Center Groningen and the CCQ official foundation platform.

Purpose

Chronic obstructive pulmonary disease represents one of the leading global causes of chronic morbidity and mortality. Historically, clinical assessment of COPD relied almost exclusively on objective physiological measurements, primarily spirometry indices such as the forced expiratory volume in one second (FEV₁) and the FEV₁/FVC ratio. However, scientific consensus has increasingly recognized that spirometric staging correlates only weakly to moderately with actual patient daily functioning, dyspnea severity, exercise intolerance, exacerbation frequency, and mental health decline. To comprehensively evaluate disease impact, patient-reported outcome measures (PROMs) became standard in research settings. Yet, established research scales like the St. George’s Respiratory Questionnaire (comprising 50 items) or the Chronic Respiratory Questionnaire (comprising 20 individualized items requiring extensive administration time) proved too cumbersome, lengthy, and mathematically complex for real-world ambulatory care, primary care consultations, and rapid triage.

The principal purpose of the Clinical COPD Questionnaire (CCQ) is to overcome these structural barriers by providing a rapid, clinically practical, comprehensive, and psychometrically robust instrument designed to measure health status in patients suffering from obstructive airway diseases, including chronic bronchitis and pulmonary emphysema. Specifically, the CCQ was designed to:

• Facilitate Routine Clinical Management: Serve as an immediate clinical communication bridge between the clinician and patient during short office visits, completing administration and manual scoring in under two minutes without requiring algorithmic software or complex domain-weighting equations.
• Evaluate Multi-Domain Disease Burden: Capture the broad biopsychosocial impact of COPD by simultaneously evaluating core respiratory symptoms (dyspnea, cough, sputum production), physical and functional activity restrictions, and emotional consequences (anxiety regarding exacerbations and disease-related depressive symptoms).
• Monitor Exacerbations and Recovery: Track acute changes in patient clinical status during disease instability, exacerbations, and therapeutic adjustments using either its standard 7-day recall version or its responsive 24-hour acute monitoring variant.
• Benchmark Therapeutic Interventions: Provide an established endpoint for clinical trials, pharmacotherapeutic interventions (e.g., long-acting bronchodilators, inhaled corticosteroids), smoking cessation protocols, and comprehensive pulmonary rehabilitation programs.
• Support Primary and Secondary Care Integration: Ensure seamless cross-sectional and longitudinal comparability across primary care clinics, specialty outpatient pulmonology practices, and clinical research trials.

Psychological Construct

The CCQ measures the overarching theoretical construct of COPD-specific health status, operationalized as the degree to which respiratory symptoms directly impair the physical capabilities, daily functioning, and psychological well-being of the patient. Rather than assessing abstract or generic quality of life (which encompasses broader socioeconomic, environmental, and interpersonal dimensions outside medical management), the CCQ targets health-related clinical status—domains directly modifiable by medical therapies, lifestyle changes, and multidisciplinary respiratory interventions.

1. Symptoms Domain (Items 1, 2, 5, and 6)

The Symptoms domain quantifies the core physical manifestations of lower airway pathology. It evaluates:

• Exertional and Resting Dyspnea (Items 1 and 2): Shortness of breath is the cardinal hallmark of ventilatory limitation and dynamic hyperinflation in COPD. The CCQ differentiates between resting dyspnea (which indicates advanced baseline ventilatory failure or acute instability) and exertional dyspnea (shortness of breath precipitated by daily physical movements).
• Hypersecretory Cough and Sputum Production (Items 5 and 6): Chronic bronchial irritation, goblet cell hyperplasia, and mucociliary clearance dysfunction cause recurrent coughing and phlegm production. These items capture chronic mucus hypersecretion, which strongly correlates with bacterial colonization, airway inflammation, and higher systemic exacerbation risk.

2. Functional State Domain (Items 7, 8, 9, and 10)

The Functional State domain operationalizes the patient’s perceived behavioral restriction across a hierarchy of physical exertion and social integration:

• Strenuous and Moderate Exertion (Items 7 and 8): Captures physical restrictions during high-demand tasks (e.g., hurrying, climbing stairs, engaging in sports) and intermediate household tasks (e.g., walking, general housework, carrying packages). This hierarchical approach identifies early mobility loss as well as intermediate physical deconditioning.
• Activities of Daily Living (ADLs) (Item 9): Evaluates basic self-care activities occurring inside the domestic setting, such as dressing and washing. Impairments at this level represent severe functional decline and loss of physical independence.
• Social and Interpersonal Engagement (Item 10): Measures the downstream interpersonal consequences of dyspnea-induced isolation. It assesses whether respiratory limitations inhibit talking, engaging with children or grandchildren, and visiting family or peers. This captures the withdrawal cycle that frequently exacerbates psychological comorbidities in chronic respiratory illness.

3. Mental State Domain (Items 3 and 4)

The Mental State domain reflects the emotional distress directly attributable to respiratory vulnerability:

• Anticipatory Anxiety and Threat Appraisal (Item 3): Captures the persistent worry regarding potential chest infections or sudden breathing deterioration. Because COPD exacerbations frequently cause life-threatening respiratory failure and emergency hospitalization, patients experience hypervigilance and anticipatory fear, creating heightened somatic focus and worsening perceived dyspnea.
• Reactive Depressive Affect (Item 4): Assesses dysphoria, demoralization, and feeling “down in the dumps” secondary to chronic respiratory limitations. This item distinguishes organic or reactive emotional distress provoked by loss of physical capability and progressive breathlessness from unrelated general mood disorders.

Theoretical Framework

The conceptual framework of the CCQ is anchored in established models of chronic illness, health-related quality of life (HRQoL), and cognitive-behavioral paradigms of respiratory disability. It primarily builds upon the Wilson and Cleary Conceptual Model of Patient Outcomes, as well as the Biopsychosocial Model of Chronic Disease originally proposed by George Engel.

The Wilson and Cleary Model of Health Outcomes

Wilson and Cleary (1995) proposed a hierarchical causal pathway linking five levels of health concepts: (1) biological and physiological variables, (2) symptom status, (3) functional status, (4) general health perceptions, and (5) overall quality of life. The CCQ deliberately operationalizes levels 2, 3, and 4 into a direct, clinically manageable framework:

• Biological/Physiological Substrate: Bronchial inflammation, loss of elastic recoil, peripheral airway narrowing, and dynamic hyperinflation form the biological root.
• Symptom Status (CCQ Symptoms): The patient experiences sensory inputs of respiratory distress (dyspnea, cough, sputum accumulation).
• Functional Status (CCQ Functional State): Symptoms lead to physical behavioral modifications, activity avoidance, and functional disability across home and social life.
• Psychological Mediation (CCQ Mental State): Subjective cognitive appraisals of symptom trajectory generate anxiety regarding health decompensation and secondary reactive depression.

Cognitive-Behavioral Fear-Avoidance Model in Respiratory Illness

The CCQ is also informed by the cycle of physical deconditioning described in pulmonary rehabilitation theory. When individuals experience acute dyspnea during exertion, they develop negative cognitive appraisals (fear of suffocation or acute exacerbation). This prompts avoidance behaviors, resulting in physical inactivity, progressive skeletal muscle atrophy, and diminished cardiopulmonary reserve. Consequently, subsequent physical exertion triggers dyspnea at even lower metabolic thresholds, reinforcing emotional distress, social isolation, and depressive feelings. The 10 items of the CCQ systematically sample each link in this self-reinforcing downward spiral.

Validity

Extensive psychometric investigations across international cohorts have validated the construct, convergent, discriminant, and predictive properties of the CCQ.

Construct and Convergent Validity

In the seminal validation study by van der Molen et al. (2003), the CCQ demonstrated powerful convergent validity when evaluated against gold-standard respiratory questionnaires:

• St. George’s Respiratory Questionnaire (SGRQ): The total CCQ score correlated strongly with the SGRQ total score (Pearson r = 0.69 to 0.81, p < 0.001). Furthermore, the CCQ Symptoms subscale correlated strongly with the SGRQ Symptoms component (r = 0.72), and the CCQ Functional subscale correlated with the SGRQ Activity component (r = 0.76).
• Chronic Respiratory Questionnaire (CRQ): Strong inverse correlations were documented between CCQ domains and CRQ domains (dyspnea, emotional function, mastery, and fatigue), with correlation coefficients ranging from r = -0.55 to -0.74.
• COPD Assessment Test (CAT): Contemporary cross-validation studies (e.g., Tsiligianni et al., 2012) have shown near-equivalence between the CCQ and the CAT, with correlations consistently exceeding r = 0.75 (p < 0.0001).

Correlation with Physiological and Functional Markers

Consistent with health status theory, CCQ scores exhibit weak-to-moderate negative correlations with airway obstruction parameters, such as FEV₁ % predicted (typically r = -0.32 to -0.45). This confirms that the CCQ captures patient-centered experiences that are not explained by spirometric values alone. Conversely, the CCQ displays stronger correlations with objective exercise capacity measures, such as the 6-Minute Walk Distance (6MWD; r = -0.40 to -0.58), demonstrating that self-reported functional limitations directly reflect objective exercise tolerance.

Discriminant and Known-Groups Validity

The CCQ demonstrates robust discriminative capacity across different disease severities classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages (GOLD 1 to 4). Mean CCQ scores rise monotonically with increasing airflow limitation and symptom burden. Furthermore, the questionnaire readily differentiates stable outpatients from individuals experiencing an acute exacerbation of COPD (AECOPD), with scores during acute decompensation averaging 1.0 to 1.5 points higher than baseline stable states.

Responsiveness and Minimal Clinically Important Difference (MCID)

The responsiveness of the CCQ to medical interventions has been established in multiple clinical contexts:

• Pulmonary Rehabilitation: Comprehensive exercise training and education programs yield statistically and clinically significant reductions in CCQ total scores, ranging from 0.45 to 0.70 points.
• Pharmacotherapy & Smoking Cessation: Introduction of dual bronchodilation (LABA/LAMA) and successful smoking cessation generate quantifiable score improvements within 2 to 12 weeks.
• Established MCID: Using both anchor-based methods (anchored against the SGRQ and Global Rating of Change scales) and distribution-based methods, the Minimal Clinically Important Difference of the CCQ is defined as 0.4 points. A change of 0.4 or greater represents a clinically meaningful difference in patient health status.

Reliability

The CCQ possesses robust reliability across diverse settings, patient populations, and language adaptations.

Internal Consistency Reliability

Internal consistency has been thoroughly evaluated across multiple global studies. In the initial validation cohort by van der Molen et al. (2003), the overall 10-item scale demonstrated high internal consistency, yielding a Cronbach’s alpha of 0.89. Across individual subscales, alpha coefficients were calculated as:

• Symptoms Subscale: Cronbach’s alpha = 0.78 to 0.81
• Functional State Subscale: Cronbach’s alpha = 0.80 to 0.88
• Mental State Subscale: Cronbach’s alpha = 0.75 to 0.82

These values fall within the optimal psychometric window (> 0.70 for research comparisons, > 0.85 for clinical evaluation) while remaining below 0.95, indicating an absence of redundant items.

Test-Retest Reliability

In stable COPD outpatients assessed over a two-week interval without therapeutic modifications, the intraclass correlation coefficient (ICC) for the overall CCQ score was 0.94 (95% CI: 0.91–0.96). Subscale test-retest ICCs similarly showed stability: Symptoms (ICC = 0.88), Functional State (ICC = 0.93), and Mental State (ICC = 0.87). In clinical studies examining the 24-hour version in hospitalized patients over stable 48-hour periods, the ICC remained high at 0.90.

Factor Analysis

The latent structural integrity of the CCQ has been scrutinized using both exploratory factor analysis (EFA) and confirmatory factor analysis (CFA).

Exploratory Factor Analysis (EFA)

During scale development, principal component analysis with varimax and oblimin rotations identified three distinct factors accounting for over 65% of the total variance:

• Factor 1 (Functional State): Items 7, 8, 9, and 10 demonstrated primary factor loadings ranging from 0.68 to 0.86, loading cleanly onto the physical/functional limitation dimension.
• Factor 2 (Symptoms): Items 1, 2, 5, and 6 loaded strongly onto the clinical respiratory symptoms dimension, with factor loadings between 0.62 and 0.84.
• Factor 3 (Mental State): Items 3 and 4 cleanly separated into an affective/emotional dimension, with factor loadings exceeding 0.78. Cross-loadings across alternative factors were low (typically < 0.30).

Confirmatory Factor Analysis (CFA)

Subsequent psychometric evaluations have examined both first-order three-factor models and hierarchical second-order models where the three dimensions load onto an overarching “COPD Health Status” latent construct. CFA fit indices from multinational studies indicate acceptable model fit:

• Comparative Fit Index (CFI): Values consistently range between 0.94 and 0.98, surpassing the traditional > 0.90 / > 0.95 thresholds.
• Tucker-Lewis Index (TLI): Consistently measured between 0.93 and 0.97.
• Root Mean Square Error of Approximation (RMSEA): Point estimates typically range between 0.048 and 0.068 (90% CI: 0.035–0.079), confirming minimal residual error.
• Standardized Root Mean Square Residual (SRMR): Typically < 0.05.

These findings justify both the calculation of domain-specific subscale means and the global composite mean score.

Instrument / Measurement Tool

• Instrument Name: Clinical COPD Questionnaire (CCQ)
• Target Population: Adults and older adults diagnosed with Chronic Obstructive Pulmonary Disease (COPD), chronic bronchitis, or emphysema.
• Administration Format: Paper-and-pencil self-report, digital questionnaire via tablet/web, or clinician-facilitated interview.
• Completion Time: Approximately 1 to 2 minutes.
• Versions:
  • Weekly Version: Assesses symptoms and limitations over “the past week” (standard for outpatient monitoring and clinical trials).
  • 24-Hour Version: Assesses symptoms and limitations over “the past 24 hours” (used for acute exacerbations, emergency triage, and day-to-day inpatient monitoring).
• Number of Items: 10 items.
• Subscales / Domains:
  • Symptoms Domain: 4 items (Items 1, 2, 5, 6)
  • Functional State Domain: 4 items (Items 7, 8, 9, 10)
  • Mental State Domain: 2 items (Items 3, 4)
• Response Format: Authentic 7-point Likert scale from 0 to 6.
  • For items 1–6 (Frequency/Severity): 0 = never, 1 = hardly ever, 2 = a few times, 3 = several times, 4 = many times, 5 = a great many times, 6 = almost all the time.
  • For items 7–10 (Limitation): 0 = not limited at all, 1 = very slightly limited, 2 = slightly limited, 3 = moderately limited, 4 = very limited, 5 = extremely limited, 6 = totally limited / or unable to do.
• Scoring Rules:
  • Every item is scored directly from 0 to 6 (no reverse scoring is needed).
  • Total CCQ Score: Calculated as the unweighted arithmetic mean of all 10 items: Total Score = (Sum of all 10 item scores) / 10. Overall scores range from 0.0 to 6.0.
  • Symptoms Subscale Score: (Item 1 + Item 2 + Item 5 + Item 6) / 4.
  • Functional State Subscale Score: (Item 7 + Item 8 + Item 9 + Item 10) / 4.
  • Mental State Subscale Score: (Item 3 + Item 4) / 2.
  • Missing Data Rule: If more than one item is missing, the total score should not be computed. If only one item is missing, calculate the mean of the remaining 9 items.
• Score Interpretation:
  • 0.0 – 1.0: Very good health status / mild disease impact (well-controlled).
  • 1.1 – 2.0: Moderate health status impairment (mild-to-moderate limitation).
  • 2.1 – 3.0: Unstable / moderately severe impairment (treatment optimization indicated).
  • > 3.0: Severe to very severe impairment (high symptom burden, marked functional limitation).
  • Minimal Clinically Important Difference (MCID): A change of 0.40 points reflects a clinically meaningful change.

Permissions & Fee and Test Year

• Year of Initial Publication: 2003.
• Original Developers: Thys van der Molen, B. W. M. Willemse, S. Schokker, Nick H. T. Ten Hacken, Dirkje S. Postma, and Elizabeth F. Juniper.
• Copyright Holder: University of Groningen / The CCQ Foundation.
• Licensing & Access Policy:
  • Routine Clinical Practice & Academic Non-Commercial Research: The CCQ is made freely available to healthcare providers, non-funded academic researchers, and registered clinical practitioners for routine patient monitoring without licensing fees.
  • Commercial & Industry-Sponsored Trials: Commercial entities, pharmaceutical manufacturers, and for-profit contract research organizations (CROs) are required to obtain a formal license and pay associated administrative and licensing fees via the official CCQ copyright management platform or University Medical Center Groningen technology transfer channels.
• Translations: The CCQ has been translated and culturally validated into more than 70 languages following standard international MAPI-style forward-backward translation protocols.

References

• van der Molen, T., Willemse, B. W. M., Schokker, S., Ten Hacken, N. H. T., Postma, D. S., & Juniper, E. F. (2003). Development, validity and responsiveness of the Clinical COPD Questionnaire. Health and Quality of Life Outcomes, 1(1), 13. https://doi.org/10.1186/1477-7525-1-13
• Kocks, J. W. H., Tuinenga, M. G., Uil, S. M., van den Berg, J. W. K., Ståhl, E., & van der Molen, T. (2006). Health status measurement in COPD: The Clinical COPD Questionnaire compared with the Severe Respiratory Insufficiency questionnaire. Respiratory Medicine, 100(11), 2007–2012. https://doi.org/10.1016/j.rmed.2006.02.019
• Tsiligianni, I. G., van der Molen, T., Moraitaki, D., Lopez-Campos, J. L., Tsagaraki, V., Siafakas, N., & Tzanakis, N. (2012). Assessing health status in COPD. A head-to-head comparison between the COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ). BMC Pulmonary Medicine, 12(1), 44. https://doi.org/10.1186/1471-2466-12-44
• Reda, A. A., Kotz, D., Kocks, J. W., Wesseling, G., & van Schayck, C. P. (2010). Reliability and validity of the Clinical COPD Questionnaire and chronic respiratory questionnaire. Respiratory Medicine, 104(11), 1675–1682. https://doi.org/10.1016/j.rmed.2010.04.024
• Canavan, J. L., Dilaver, D., Clark, A. L., Jones, S. E., Nolan, C. M., Kon, S. S., & Man, W. D. C. (2014). Clinical COPD Questionnaire (CCQ) as a screening tool for depression in patients with COPD. Thorax, 69(Suppl 2), A175–A176. https://doi.org/10.1136/thoraxjnl-2014-206260.364
• Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA, 273(1), 59–65. https://doi.org/10.1001/jama.1995.03520250075037

Items of the Scale